415 Capital Management

What they fund

• Stage — Seed to growth stage, with a focus on clinical-stage and commercial-stage companies [1].
• Sector — Medtech, biotech, medical devices, therapeutics, and diagnostics [1].
• Geography — Europe, Israel, and the US [1].
• Company Shape — Companies developing breakthrough and life-saving medical innovations, with a focus on clinical insights and market access [1].
• Investment Size — Not disclosed, but the firm's track record of over 125 exits suggests a capacity for significant investments [1].

Investment thesis

415 Capital Management is a specialist venture capital firm dedicated to investing in breakthrough and life-saving medical innovation, providing capital, expertise, and market access to entrepreneurs [1].

• Mission — Dedicated to funding "life-saving innovation" and unlocking medical breakthroughs through capital, expertise, and market access [1].
• Domain Expertise — Leverages a team with backgrounds in medicine, biomedical engineering, regulatory affairs, and medical device commercialization to identify high-potential innovations [1].
• Clinical Insight — Utilizes a proprietary Clinical Team of physicians and specialists to gain insights into day-to-day clinical practice and patient care needs [1].
• Long-term Horizon — Operates with over 25 years of experience, indicating a patient, long-term investment horizon focused on deep tech and medtech [1].

Credibility: The firm's own website outlines its mission, team composition, and investment strategy, providing direct evidence of its focus on medical innovation and clinical insights.

Interconnection: The firm's clinical team and domain expertise directly inform its investment thesis, allowing it to identify and support high-potential medical innovations.

Credibility: The firm's website provides detailed information about its team, investment strategy, and portfolio, confirming its focus on medical innovation and clinical insights.

Value add

415 Capital Management provides exceptional entrepreneurs with capital, expertise, and market access [1].

• Clinical Insights — Access to a proprietary Clinical Team of physicians and specialists for insights into clinical practice and patient care needs [1].
• Domain Expertise — Team with backgrounds in medicine, biomedical engineering, regulatory affairs, and medical device commercialization [1].
• Market Access — Leveraging a network of clinical advisors and a clinical network to facilitate market access for portfolio companies [1].
• Value Creation — Focus on value creation through strategic guidance and support for portfolio companies [1].

Fit verdict: 415 Capital Management is an ideal partner for medtech and biotech startups seeking capital, clinical insights, and market access.

Founder diligence script:

• What specific clinical insights can you provide for our technology?
• How do you facilitate market access for your portfolio companies?
• Can you share examples of successful value creation with previous portfolio companies?
• What is your typical investment size and stage?
• How do you support regulatory affairs and commercialization?

Portfolio focus

• CardioVentures — Focus on cardiovascular technologies, including companies like Endovascular Engineering and Supira Medical [1].
• 415 Capital — Broader medtech focus, including companies like Laza Medical and CorFlow Therapeutics [1].
• Active Investments — Over 25 active investments, with a strong emphasis on clinical-stage and commercial-stage companies [1].
• Exits — Over 125 realized exits, including trade-sales and IPOs, demonstrating a track record of successful exits [1].
• Portfolio Diversity — Portfolio includes companies in endovascular, cardiovascular robotics, ventricular assist devices, and surgical robotics [1].

Notable investments & exits

• CardioVentures — Over 125 realized exits, including trade-sales and IPOs [1].
• 415 Capital — Over 125 realized exits, including trade-sales and IPOs [1].
• Exits — The firm's track record of over 125 exits demonstrates a successful exit strategy [1].
• Exits — The firm's focus on clinical-stage and commercial-stage companies suggests a focus on late-stage exits [1].
• Exits — The firm's network of clinical advisors and clinical network may facilitate exits for portfolio companies [1].

Strategic implications

415 Capital Management's focus on clinical insights and market access provides a competitive edge in the medtech and biotech sectors. The firm's long-term horizon and track record of successful exits suggest a patient, value-driven investment approach. The firm's network of clinical advisors and clinical network may facilitate market access and exits for portfolio companies.

Where they could go further

415 Capital Management could expand its focus to include early-stage medtech startups, providing capital and support at an earlier stage. The firm could enhance its value proposition by offering more structured support for regulatory affairs and commercialization. 415 Capital Management could expand its geographic focus to include emerging markets, providing access to new opportunities.